Panel Community Conversations track
Real-Life Management of Primary Sclerosing Cholangitis and Primary Sclerosing Cholangitis–Inflammatory Bowel Disease: Integrating Liver and Bowel Care
Sat, Nov 7, 2026 · 9:45–10:45 AM MST Convention Center: Bluebird Ballroom 3GH, Colorado Convention Center
About this session
Primary sclerosing cholangitis (PSC) remains without an approved medical therapy, leaving clinicians to navigate highly variable and often conflicting real-world practices. Many patients receive ursodiol; others receive oral vancomycin (OV), and bowel-directed therapies that are inconsistently integrated despite strong evidence that PSC is a gut-liver axis disease.
Speakers
-
Stanford University Medical Center
Panelist
Reviews of this session
No reviews yet
Were you in the room? Reviews are open until Nov 9, 2027.